1. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial. (7th April 2022) Authors: Chen, Peter; Behre, Gerhard; Hebert, Corey; Kumar, Princy; Farmer Macpherson, Lisa; Graham-Clarke, Peita Louise; De La Torre, Inmaculada; Nichols, Russell M; Hufford, Matthew M; Patel, Dipak R; Naegeli, April N Journal: Open forum infectious diseases Issue: Volume 9:Number 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗